1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

NCT04150900 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma

Interventions

DRUG: Bavituximab
DRUG: Pembrolizumab

Sponsor

University of Maryland, Baltimore